ADVI Analysis: MACPAC November 2023 Meeting

Pharmaceuticals and Biotech Pharmaceuticals and Biotech

November 15, 2023

MACPAC held a meeting November 2-3, 2023 (link). The following relevant topics were discussed:

  • Improving the Managed Care Appeals Process
  • Unwinding the Continuous Coverage Requirement in Medicaid: State and Managed Care Plan Strategies

ADVI Angle

Key takeaways from the November meeting include:

  • Improving the Managed Care Appeals Process
    • Commissioners largely supported the following policy options, although some expressed concerns with the first:
      1. CMS should require states to establish an independent, external medical review process for beneficiaries.
      2. CMS should issue rulemaking and guidance on continuation of benefits.
      3. CMS should issue guidance to improve beneficiary access to and support throughout the appeals process.
      4. CMS should require that managed care organizations (MCOs) provide beneficiaries with a choice to receive notices in an electronic format.
    • At the January 2024 MACPAC meeting, staff will present a draft chapter on this topic and Commissioners will vote on the policy recommendations.
  • Unwinding the Continuous Coverage Requirement in Medicaid: State and Managed Care Plan Strategies
    • Several panelists presented on state and managed care organization (MCO) strategies used during the Medicaid redeterminations process.
    • Commissioners supported the continued use of temporary flexibilities after unwinding, state strategies to increase outreach to members, and increased data collection.
    • Commissioners supported more integration between assistance programs (e.g., SNAP, Medicaid).

This is an abridged and delayed release. Full ADVI Analysis content is distributed in real time for retainer clients. Get in touch to learn more about how we can support your commercialization, market access, and policy needs.


CEO insights

Real analysis from people who’ve been there

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

Cell and Gene

Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care

CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …

Alicia Silver, MPP
November 21, 2025

Inflation Reduction Act Pharmaceuticals and Biotech

Why is Medicare Data Central to IRA Negotiations?

The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …

September 10, 2025

Pharmaceuticals and Biotech

ADVI Analysis: MACPAC October 2024 Meeting

MACPAC held a meeting on October 31 and November 1, 2024 (link). The following relevant topics were discussed: ADVI Angle …

November 11, 2024

Inflation Reduction Act Pharmaceuticals and Biotech State Policy

ADVI Instant: CMS Releases 2026 Notice of Benefit and Payment Parameters Proposed Rule

On October 4, 2024, the Centers for Medicare and Medicaid Services (CMS) released a proposed rule titled “HHS Notice of …

Brenna Raines, MHA
October 21, 2024

Pharmaceuticals and Biotech

ADVI Analysis: MedPAC October 2024 Meeting

MedPAC held a meeting on October 10-11, 2024 (link). The following relevant topics were discussed: ADVI Angle Key takeaways from …

October 21, 2024

Inflation Reduction Act Pharmaceuticals and Biotech

ADVI Instant: CMS Finalizes Guidance on IPAY 2027 Negotiation and MFP Implementation for 2026/27

On October 2, 2024, CMS issued final guidance on the Medicare Drug Price Negotiation Program for IPAY 2027 and Manufacturer …

Lindsay Bealor Greenleaf, JD, MBA
October 11, 2024

Pharmaceuticals and Biotech

ADVI Instant: CMS Releases Medicaid Drug Rebate Program Final Rule

On September 20, 2024, the Centers for Medicare and Medicaid Services (CMS) released a Final Rule titled “Misclassification of Drugs, …

Lindsay Bealor Greenleaf, JD, MBA
September 27, 2024

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.